Tenaya Therapeutics (Tenaya Therapeutics) Operating Cash Flow per Share : $-1.33 (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Tenaya Therapeutics Operating Cash Flow per Share?

Tenaya Therapeutics's operating cash flow per share for the three months ended in Mar. 2024 was $-0.35. Tenaya Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.33.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -2.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Tenaya Therapeutics's Operating Cash Flow per Share or its related term are showing as below:

TNYA' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -37.8 Med: -19.9 Max: -2
Current: -2

During the past 5 years, Tenaya Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was -2.00% per year. The lowest was -37.80% per year. And the median was -19.90% per year.

TNYA's 3-Year OCF Growth Rate is ranked worse than
57.7% of 1234 companies
in the Biotechnology industry
Industry Median: 3.5 vs TNYA: -2.00

Tenaya Therapeutics Operating Cash Flow per Share Historical Data

The historical data trend for Tenaya Therapeutics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tenaya Therapeutics Operating Cash Flow per Share Chart

Tenaya Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

-0.89

-1.30

-3.43

-2.33

-1.38

Tenaya Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Operating Cash Flow per Share	Get a 7-Day Free Trial													-0.41	-0.36	-0.32	-0.30	-0.35

Competitive Comparison of Tenaya Therapeutics's Operating Cash Flow per Share

For the Biotechnology subindustry, Tenaya Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tenaya Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tenaya Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Tenaya Therapeutics's Price-to-Operating-Cash-Flow falls into.

Tenaya Therapeutics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Tenaya Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-102.072	/	73.786
	=	-1.38

Tenaya Therapeutics's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )	=	Cash Flow from Operations (Q: Mar. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
	=	-28.66	/	80.982
	=	-0.35

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.33

Tenaya Therapeutics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Tenaya Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Tenaya Therapeutics (Tenaya Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tenaya Therapeutics Inc (NAS:TNYA) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

171 Oyster Point Boulevard, Suite 500, South San Francisco, CA, USA, 94080

Website

https://www.tenayatherapeutics.com

Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.

Executives

Timothy Hoey	officer: Chief Scientific Officer	C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, 5TH FLR., SOUTH SAN FRANCISCO CA 94080
Leone D Patterson	officer: Chief Fin and Bus. Officer
Whittemore Tingley	officer: Chief Medical Officer	C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Faraz Ali	director, officer: Chief Executive Officer	C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BLVD., 5TH FLR., SOUTH SAN FRANCISCO Z4 94080
David V Goeddel	director, 10 percent owner	C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iii Gp, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Amy L. Burroughs	director	TWO CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Column Group Iii, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Opportunity Iii Gp, Lp	10 percent owner	1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Tcg Opportunity Iii Gp, Llc	10 percent owner	1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Column Group Opportunity Iii, Lp	10 percent owner	1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Deepak Srivastava	director	C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Column Group Iii-a, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Eli Casdin	director	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Capital, Llc	director	1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019